How many MSM in Europe could benefit from PrEP--a 9 billion Euro question?

Int J STD AIDS. 2015 Nov;26(13):988-90. doi: 10.1177/0956462415584490.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Anti-Retroviral Agents / economics
  • Anti-Retroviral Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Europe
  • HIV Infections / economics
  • HIV Infections / prevention & control*
  • Health Care Costs / statistics & numerical data*
  • Homosexuality, Male / statistics & numerical data*
  • Humans
  • Male
  • Pre-Exposure Prophylaxis / methods*

Substances

  • Anti-Retroviral Agents